Nykode Therapeutics Announces First Subject Dosed With Its T Cell Focused Next-generation SARS-CoV-2 Vaccine Candidate

Published by
The Street

By GlobeNewswire First subject dosed with Nykode Therapeutics’ T cell focused SARS-CoV-2 vaccine candidate. This is part of the ongoing phase 1/2 two-arm clinical trial VB-D-01 designed to specifically address emerging variants of concern, including Omicron 1The T cell focused vaccine candidate (VB10.2210) encodes 96 clinically validated T cell epitopes spanning a total of eight SARS-CoV-2 proteins, including Spike. These Spike- and non-Spike T cell epitopes have been identified and validated by Adaptive Biotechnologies using their immune medicine platformInitial analysis indicates that no epi…

Read More

Related Articles